Drugs / NXL-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06761183 | Jan 2025 → Dec 2026 expected | ischemic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXL-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06761183 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “NXL-001 is a gene therapy, using an AAV9 (adeno-associated virus 9) vector” NCT06761183 ↗ |
| Route | Other | “intracerebral stereotactic injection of NXL-001” NCT06761183 ↗ |